Pliant Therapeutics Announces Four Upcoming Presentations at the European Respiratory Society International Congress 2024
26 août 2024 09h10 HE
|
Pliant Therapeutics, Inc.
SOUTH SAN FRANCISCO, Calif., Aug. 26, 2024 (GLOBE NEWSWIRE) -- Pliant Therapeutics, Inc. (Nasdaq: PLRX), a late-stage biotechnology company and leader in the discovery and development of novel...
Pliant Therapeutics Provides Corporate Update and Reports Second Quarter 2024 Financial Results
07 août 2024 16h05 HE
|
Pliant Therapeutics, Inc.
Positive data from a 12-week Phase 2a PET imaging trial demonstrated reduced total lung collagen, improved FVC and reduced cough severity in IPF patients treated with bexotegrast Positive...
Pliant Therapeutics to Participate in the Canaccord Genuity 44th Annual Growth Conference
06 août 2024 16h03 HE
|
Pliant Therapeutics, Inc.
SOUTH SAN FRANCISCO, Calif., Aug. 06, 2024 (GLOBE NEWSWIRE) -- Pliant Therapeutics, Inc. (Nasdaq: PLRX) today announced that Keith Cummings, M.D., Chief Financial Officer, and Éric Lefebvre, M.D.,...
Pliant Therapeutics Announces Positive Long-Term Data from the INTEGRIS-PSC Phase 2a Trial Demonstrating Bexotegrast was Well Tolerated at 320 mg with Continued Antifibrotic and Anti-Cholestatic Activity Displayed Across Multiple Measures
15 juil. 2024 08h00 HE
|
Pliant Therapeutics, Inc.
Bexotegrast at 320 mg was well tolerated up to 40 weeks of treatment with no treatment-related severe or serious adverse events 320 mg cohort demonstrated improvement in liver stiffness by...
Pliant Therapeutics Announces Appointment of Steve Krognes to Board of Directors
13 juin 2024 16h05 HE
|
Pliant Therapeutics, Inc.
SOUTH SAN FRANCISCO, June 13, 2024 (GLOBE NEWSWIRE) -- Pliant Therapeutics, Inc. (Nasdaq: PLRX), a late-stage biotechnology company and leader in the discovery and development of novel therapeutics...
Pliant Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
12 juin 2024 16h05 HE
|
Pliant Therapeutics, Inc.
SOUTH SAN FRANCISCO, Calif., June 12, 2024 (GLOBE NEWSWIRE) -- Pliant Therapeutics, Inc. (Nasdaq: PLRX), today announced that on June 10, 2024, it granted stock options to purchase an aggregate of...
Pliant Therapeutics Presents Data from its Bexotegrast Program at the European Association for the Study of the Liver (EASL) International Liver Congress™
06 juin 2024 08h00 HE
|
Pliant Therapeutics, Inc.
SOUTH SAN FRANCISCO, Calif., June 06, 2024 (GLOBE NEWSWIRE) -- Pliant Therapeutics, Inc. (Nasdaq: PLRX), a late-stage biotechnology company and leader in the discovery and development of novel...
Pliant Therapeutics Presents Data from its Bexotegrast Program at the American Thoracic Society International Conference
21 mai 2024 18h50 HE
|
Pliant Therapeutics, Inc.
SOUTH SAN FRANCISCO, Calif., May 21, 2024 (GLOBE NEWSWIRE) -- Pliant Therapeutics, Inc. (Nasdaq: PLRX), a clinical-stage biotechnology company and leader in the discovery and development of novel...
Pliant Therapeutics Announces Positive Topline Data from a Phase 2a Collagen PET Imaging Clinical Trial of Bexotegrast in Patients with Idiopathic Pulmonary Fibrosis
14 mai 2024 07h30 HE
|
Pliant Therapeutics, Inc.
12-week treatment with Bexotegrast 160 mg resulted in reduction of total lung collagen as measured by PET imaging, compared to an increase on placebo Improvement in FVC and reduction in...
Pliant Therapeutics Announces Upcoming Presentations at the European Association for the Study of the Liver International Liver Congress™
07 mai 2024 08h00 HE
|
Pliant Therapeutics, Inc.
SOUTH SAN FRANCISCO, Calif., May 07, 2024 (GLOBE NEWSWIRE) -- Pliant Therapeutics, Inc. (Nasdaq: PLRX), a late-stage biotechnology company and leader in the discovery and development of novel...